Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $79.00 by Analysts at Canaccord Genuity Group

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lowered by Canaccord Genuity Group from $128.00 to $79.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on RARE. HC Wainwright dropped their price objective on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. Wells Fargo & Company dropped their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. Robert W. Baird lowered their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. TD Cowen dropped their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Wedbush reaffirmed a “neutral” rating and set a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $68.29.

Ultragenyx Pharmaceutical Trading Up 1.3%

Shares of Ultragenyx Pharmaceutical stock opened at $20.45 on Wednesday. The company has a market cap of $1.97 billion, a PE ratio of -3.50 and a beta of 0.16. The company has a 50 day moving average of $25.96 and a 200-day moving average of $29.60. Ultragenyx Pharmaceutical has a 1-year low of $18.41 and a 1-year high of $45.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 566.58%. The firm had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. During the same period last year, the business earned ($1.39) earnings per share. The business’s revenue was up 25.5% compared to the same quarter last year. Research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $23.56, for a total value of $72,117.16. Following the sale, the chief financial officer owned 88,935 shares in the company, valued at approximately $2,095,308.60. The trade was a 3.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold 6,227 shares of company stock valued at $187,126 in the last three months. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in RARE. Mercer Global Advisors Inc. ADV lifted its stake in shares of Ultragenyx Pharmaceutical by 17.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 2,036 shares during the period. Krensavage Asset Management LLC bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $3,442,000. Empowered Funds LLC acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $66,000. XTX Topco Ltd lifted its stake in Ultragenyx Pharmaceutical by 734.8% in the fourth quarter. XTX Topco Ltd now owns 119,996 shares of the biopharmaceutical company’s stock valued at $2,760,000 after buying an additional 105,622 shares during the period. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 33.3% during the 4th quarter. Voloridge Investment Management LLC now owns 643,356 shares of the biopharmaceutical company’s stock worth $14,797,000 after buying an additional 160,774 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Canaccord lowered its price target to $79 from $128 but maintained a “buy” rating, citing continued upside potential (the new PT implies large upside versus current levels). Canaccord PT Cut
• Positive Sentiment: HC Wainwright cut its target to $50 (from $60) while keeping a “buy” rating, signaling broker confidence in longer‑term value despite lowering near‑term expectations. HC Wainwright Coverage
• Neutral Sentiment: Wedbush reaffirmed a “neutral” rating with a $25 price target, reflecting a more cautious near‑term view and limited upside relative to the current price. Wedbush Note
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Levi & Korsinsky, Robbins LLP, Berger Montague, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, The Gross Law Firm, Kahn Swick & Foti, Schall Law Firm and others) have filed or are soliciting investors to join a securities‑class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are urging appointment of a lead plaintiff by April 6, 2026 — this creates legal and financial uncertainty (potential discovery, defense costs, settlement risk). Representative notices: Gross Law Firm Notice Levi & Korsinsky Notice Rosen Law Firm Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.